
Overwhelmed and Underdiagnosed: Understanding ADHD in Female Patients
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in females. The presence of comorbid psychiatric disorders, including depression and anxiety, and obsessive compulsive disorder, may mitigate symptoms and delay diagnosis. The short-term effects of undiagnosed or undertreated ADHD in females presents a range of academic and social problems during childhood and adolescence. This course will provide participants an overview of current diagnostic practices and emerging treatment for ADHD in females.
This session is supported by an educational grant from Supernus Pharmaceuticals.
This activity is provided by Global Education Group
Target Audience
The educational design of this activity addresses the needs of internists, neurologists, psychiatrists, ADHD specialists, pediatricians, nurse practitioners, primary care physicians, physician associates, pharmacists, and other HCPs involved in the treatment of patients with ADHD.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the differences in clinical presentation, comorbidity, and functioning for girls and women with ADHD
- Discuss the burden of a delayed diagnosis on females with ADHD
- Highlight the challenges of stimulant use for the treatment of ADHD in females
- Review the efficacy and safety profiles of emerging non-stimulant treatments for ADHD
Jay Salpekar, MD, FANPA, FAES, DFAACAP
Associate Professor of Psychiatry and Neurology
Johns Hopkins University School of Medicine
Baltimore, MD
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-0000-22-358-H01-P)
This is a knowledge-based activity.
Term Offering
This activity was released on 12/15/2022 and is valid for one year. Requests for credit must be made no later than 12/15/2023.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete and pass the posttest with a score of at least 70% and complete the evaluation/application for credit. Certificates will then be available for download. Pharmacists: Credit will be awarded via CPE Monitor 60 days post the enduring meeting
Fee & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter | Reported Financial Relationship |
Jay Salpekar | Contracted Research (Principal Investigators must provide information, even if received by the institution): Jazz Pharmaceuticals |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.00 ACCME (All Other)
- 1.00 ACCME (MD/DO Only)
- 1.00 ACPE Pharmacy
- 1.00 ANCC